Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 327

1.

Serious Games for Health: Features, Challenges, Next Steps.

Blumberg MF, Burke LC, Hodent PC, Evans MA, Lane HC, Schell J.

Games Health J. 2014 Oct;3(5):270-6. doi: 10.1089/g4h.2014.0079.

PMID:
26192481
2.

HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls.

Swaminathan S, Sui H, Adelsberger JW, Chen Q, Sneller M, Migueles SA, Kottilil S, Ober A, Jones S, Rehm CA, Lane HC, Imamichi T.

J AIDS Clin Res. 2014 Jun;5(6). pii: 315.

3.

Activated platelet-T-cell conjugates in peripheral blood of patients with HIV infection: coupling coagulation/inflammation and T cells.

Green SA, Smith M, Hasley RB, Stephany D, Harned A, Nagashima K, Abdullah S, Pittaluga S, Imamichi T, Qin J, Rupert A, Ober A, Lane HC, Catalfamo M.

AIDS. 2015 Jul 17;29(11):1297-308. doi: 10.1097/QAD.0000000000000701.

PMID:
26002800
4.

Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States.

Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, Barrett K, Wolcott MJ, Marconi VC, Lyon GM 3rd, Weinstein GL, Weinmeister K, Sutton S, Hazbun M, Albariño CG, Reed Z, Cannon D, Ströher U, Feldman M, Ribner BS, Lane HC, Fauci AS, Uyeki TM.

Ann Intern Med. 2015 Jul 21;163(2):81-90. doi: 10.7326/M15-0530.

PMID:
25961438
5.

State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus.

Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT.

J Infect Dis. 2015 May 9. pii: jiv115. [Epub ahead of print]

PMID:
25957962
6.

Tuberculosis specific responses following therapy for TB: Impact of HIV co-infection.

Siddiqui S, Sarro Y, Diarra B, Diallo H, Guindo O, Dabitao D, Tall M, Hammond A, Kassambara H, Goita D, Dembele P, Traore B, Hengel R, Nason M, Warfield J, Washington J, Polis M, Diallo S, Dao S, Koita O, Lane HC, Catalfamo M, Tounkara A.

Clin Immunol. 2015 Jul;159(1):1-12. doi: 10.1016/j.clim.2015.04.002. Epub 2015 Apr 15.

PMID:
25889622
7.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary Report.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Bliss RL, Cebrik D, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2015 Apr 1. [Epub ahead of print]

8.

Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ Jr, Rubinson L, Ströher U, Wolcott M, Dorman W, Uyeki TM, Feldmann H, Lane HC, Mulligan MJ.

JAMA. 2015 Mar 24-31;313(12):1249-55. doi: 10.1001/jama.2015.1995.

PMID:
25742465
9.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.

PMID:
25403209
10.

Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.

Lynfield R, Davey R, Dwyer DE, Losso MH, Wentworth D, Cozzi-Lepri A, Herman-Lamin K, Cholewinska G, David D, Kuetter S, Ternesgen Z, Uyeki TM, Lane HC, Lundgren J, Neaton JD; INSIGHT Influenza Study Group.

PLoS One. 2014 Jul 8;9(7):e101785. doi: 10.1371/journal.pone.0101785. eCollection 2014.

11.

Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection.

Swaminathan S, Hu Z, Rupert AW, Higgins JM, Dewar RL, Stevens R, Chen Q, Rehm CA, Metcalf JA, Baseler MW, Lane HC, Imamichi T.

PLoS One. 2014 Jun 4;9(6):e98989. doi: 10.1371/journal.pone.0098989. eCollection 2014.

12.

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

Revell AD, Boyd MA, Wang D, Emery S, Gazzard B, Reiss P, van Sighem AI, Montaner JS, Lane HC, Larder BA.

HIV Med. 2014 Aug;15(7):442-8. doi: 10.1111/hiv.12156. Epub 2014 Apr 15.

PMID:
24735474
13.

Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis.

Le Saout C, Hasley RB, Imamichi H, Tcheung L, Hu Z, Luckey MA, Park JH, Durum SK, Smith M, Rupert AW, Sneller MC, Lane HC, Catalfamo M.

PLoS Pathog. 2014 Mar 6;10(3):e1003976. doi: 10.1371/journal.ppat.1003976. eCollection 2014 Mar.

14.

Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus.

Imamichi H, Natarajan V, Adelsberger JW, Rehm CA, Lempicki RA, Das B, Hazen A, Imamichi T, Lane HC.

AIDS. 2014 May 15;28(8):1091-9. doi: 10.1097/QAD.0000000000000223.

PMID:
24492253
15.

HIV/IL-2 and EBV-associated lymphoproliferative diseases: cause and effect or coincidence?

Sneller MC, Lane HC.

HIV Med. 2014 Jan;15(1):1-2. doi: 10.1111/hiv.12092. No abstract available.

PMID:
24299219
16.

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing A, Reiss P, van Sighem AI, Nelson M, Emery S, Montaner JS, Lane HC, Larder BA; RDI Study Group.

J Antimicrob Chemother. 2014 Apr;69(4):1104-10. doi: 10.1093/jac/dkt447. Epub 2013 Nov 24.

17.

Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting.

Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JS, Lane HC, Larder BA.

Biomed Res Int. 2013;2013:579741. doi: 10.1155/2013/579741. Epub 2013 Sep 24.

18.

siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway.

Sui H, Zhou M, Chen Q, Lane HC, Imamichi T.

Nucleic Acids Res. 2014 Jan;42(1):583-98. doi: 10.1093/nar/gkt844. Epub 2013 Sep 18.

19.

HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127.

Hasley RB, Hong C, Li W, Friesen T, Nakamura Y, Kim GY, Park JH, Hixon JA, Durum S, Hu Z, Sneller MC, Oguariri R, Imamichi T, Lane HC, Catalfamo M.

AIDS. 2013 Jul 31;27(12):1867-77. doi: 10.1097/QAD.0b013e3283618487.

PMID:
23965471
20.

Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

Swaminathan S, Dai L, Lane HC, Imamichi T.

Cytokine Growth Factor Rev. 2013 Dec;24(6):571-7. doi: 10.1016/j.cytogfr.2013.07.001. Epub 2013 Aug 17. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk